Patient-Derived Xenograft/PDX Model Market 2021-2027

Description

List of Tables

Full-title:Global Patient-Derived Xenograft/PDX Model Market Size, Share & Trends Analysis Report By Type (Mice Model, and Rat Model) By Tumor Models (Gynecological, Gastrointestinal, Respiratory Tumor Model and Others) By Application (Preclinical drug development, Biomarker analysis, and Basic Cancer Research) By End-User (Pharmaceutical & Biotechnology Companies, CROs, and Academic & Research Institutions) Forecast, 2021-2027.

The PDX model market is anticipated to grow at a substantial CAGR of 15.5% during the forecast period. The global PDX model market is majorly driven by the factors such as the rising prevalence of cancer and associated studies in major economies, high demand for personalized medicines, investment in pharmaceutical R&D, and increasing adoption of PDX models in various applications. The PDX model found its major use in applications such as preclinical drug development, biomarker analysis, and basic cancer research. Moreover, the high cost associated with personalized PDX models may become the restrain in the growth of the market during the forecast period. Besides, the rising demand for personalized PDX models for cancer research in major economies will create lucrative growth opportunities during the forecast period.

The global PDX model market is segmented based on type, tumor models, application, and end-user. Based on type, the market is bifurcated into mice model, and rate model. The rat model segment is accounted for the largest growth rate during the forecast period. Based on tumor models, the market is again classified into gynecological tumor model, gastrointestinal tumor model, respiratory tumor model, and others. Among these, the respiratory tumor models segment leads the market during the forecast period. Similarly, based on application, the market is categorized into preclinical drug development, biomarker analysis, and basic cancer research. The preclinical drug development segment held the largest share in the market, and it is projected to grow at a significant CAGR during the forecast period. Whereas, based on end-user, the market is further divided into pharmaceutical & biotechnology companies, CROs, hospitals and surgical centers, academic & research institutions, and others. Among these, the Preclinical drug development segment is expected to hold the largest share and the CRO segment is expected to be the fastest-growing during the forecast period owing to the increasing pharmaceutical companies hiring for CRO for the outsourcing of their preclinical studies.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is anticipated to lead the market during the forecast period. The rising awareness regarding PDX models and personalized medicines among the population is the major factor driving the growth of the market. The rise in funding initiatives by the government, and the rising incidence of cancer are also boosting the growth of the market in the region. Whereas Asia-Pacific is expected to grow at a faster rate during the forecast period. Growing drug discovery by research institutes, increasing government initiatives for healthcare research, growing disposable income, and development in healthcare infrastructure are some of the prominent factors that have accelerated the growth of the market.

Furthermore, Champions Oncology, Inc., Charles River Laboratories International, Inc., Envigo RMS LLC, EPO Berlin-Buch GmbH, Genesis Biotechnology Group, Hera Biolabs, JSR Corp, among others. These market players adopt strategies such as product launches, partnership collaborations, mergers and acquisitions, business expansion, among others to remain in the competition. For instance, in November 2019, Hamilton-based Genesis Drug Discovery & Development announced the acquisition of New England Discovery Partners, a contract research organization specializing in synthetic and medicinal chemistry. By acquiring NEDP's chemistry service portfolio, the GD3 expanded its preclinical drug research and discovery services.

Research Methodology

The market study of the global PDX model market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market.

Whitepapers, research papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global PDX model Market Research and Analysis by Type

Global PDX model Market Research and Analysis by Tumor Model

Global PDX model Market Research and Analysis by Application

Global PDX model Market Research and Analysis by End-User

The Report Covers

Comprehensive research methodology of the global PDX model market.

This report also includes a detailed and extensive market overview with key analyst insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global PDX model market.

Insights about market determinants that are stimulating the global PDX model market.

Detailed and extensive market segments with the regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Product Code: OMR2023884

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global PDX Model Industry
Recovery Scenario of Global PDX Model Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Geography

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Trade Analysis
- 2.2.3. Porter's Analysis
- 2.2.4. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
- 3.1.1. Overview
- 3.1.2. Financial Analysis
- 3.1.3. SWOT Analysis
- 3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on key players

4. Market Determinants

4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation

5.1. Global PDX Model Market, ByType
- 5.1.1. Mice Model
- 5.1.2. Rat Model
5.2. Global PDX Model Market, ByTumor Models
- 5.2.1. Gynecological Tumor Model
- 5.2.2. Gastrointestinal Tumor Model
- 5.2.3. Respiratory Tumor Model
- 5.2.4. Others
5.3. Global PDX Model Market, ByApplication
- 5.3.1. Preclinical drug development
- 5.3.2. Biomarker analysis
- 5.3.3. Basic Cancer Research
5.4. Global PDX Model Market, By End-User
- 5.4.1. Pharmaceutical & Biotechnology Companies
- 5.4.2. Contract research organizations (CROs)
- 5.4.3. Academic & Research Institutions

6. Regional Analysis

6.1. North America
- 6.1.1. United States
- 6.1.2. Canada
6.2. Europe
- 6.2.1. UK
- 6.2.2. Germany
- 6.2.3. Italy
- 6.2.4. Spain
- 6.2.5. France
- 6.2.6. Rest of Europe
6.3. Asia-Pacific
- 6.3.1. China
- 6.3.2. India
- 6.3.3. Japan
- 6.3.4. South Korea
- 6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
- 6.4.1. Latin America
- 6.4.2. Middle East & Africa

7. Company Profiles

7.1. Abnova Corp.
7.2. Aragen Life Sciences Pvt. Ltd.
7.3. Biocytogen
7.4. Champions Oncology, Inc.
7.5. Charles River Laboratories International, Inc.
7.6. Crown Bioscience Inc.,
7.7. Envigo RMS LLC
7.8. EPO Berlin-Buch GmbH
7.9. ExploraBioLabs
7.10. Genesis Biotechnology Group
7.11. Hera Biolabs
7.12. Horizon Discovery Ltd.
7.13. JSR Corp.
7.14. Living Tumor Laboratory
7.15. Oncodesign
7.16. Pharmatest Services
7.17. Shanghai LIDE Biotech Co., Ltd.
7.18. The Jackson Laboratory
7.19. Urosphere SAS
7.20. WuXiAppTec
7.21. XenTech SAS